http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 21 Oct 2026 06:06:04 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Vor+Biopharma%2C+Inc.+%28VOR%29+at+Outperform/27212395.html (Updated - October 21, 2026 6:06 AM EDT) <p>William Blair analyst Myles Minter initiates coverage on Vor Biopharma, Inc. (NASDAQ: VOR) with a Outperform rating.</p><p>The analyst comments "We are initiating coverage of Xilio Therapeutics (XLO) with an Outperform rating and a price target of $16. Our thesis is predicated on three key points: 1) Xilio has administered its masking technology in multiple clinical programs with manageable safety and tolerability, 2) Xilio can leverage its current financial outlook to transition from legacy programs into modalities with a higher likelihood of success, namely masked T-cell engagers (TCEs), and 3) collaborations with pharma provide http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Vor+Biopharma%2C+Inc.+%28VOR%29+at+Outperform/27212395.html Wed, 21 Oct 2026 06:06:04 -0400 VOR http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Vor+Biopharma%2C+Inc.+%28VOR%29+at+Outperform/27212395.html (Updated - October 21, 2026 6:06 AM EDT) <p>William Blair analyst Myles Minter initiates coverage on Vor Biopharma, Inc. (NASDAQ: VOR) with a Outperform rating.</p><p>The analyst comments "We are initiating coverage of Xilio Therapeutics (XLO) with an Outperform rating and a price target of $16. Our thesis is predicated on three key points: 1) Xilio has administered its masking technology in multiple clinical programs with manageable safety and tolerability, 2) Xilio can leverage its current financial outlook to transition from legacy programs into modalities with a higher likelihood of success, namely masked T-cell engagers (TCEs), and 3) collaborations with pharma provide http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Vor+Biopharma%2C+Inc.+%28VOR%29+at+Outperform/27212395.html Wed, 21 Oct 2026 06:06:04 -0400 VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR